Developing selective biotherapeutics for neurodegenerative disorders

Who we are

Delta Crystallon is a privately owned, clinical stage bio­pharma­ceutical company dedicated to the development of selective bio­pharma­ceuticals for neuro­degenerative disorders.

Delta Crystallon targets multiple sclerosis and the devastating orphan diseases amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP).

Our lead product

Delta Crystallon’s lead product is based on the small heat shock protein alpha B-crystallin. It offers neuroprotection, promotes immunological tolerance, and it prevents the aggregation of abnormal protein aggregates, which is a frequent pathogenic factor in neurodegenerative disorders.

Read more »